Vaxcyte Inc Dossier
Qualitative Analysis
Business overview
Vaxcyte, Inc. (NASDAQ: PCVX) is a clinical-stage vaccine innovation company dedicated to engineering high-fidelity vaccines designed to protect humankind from the consequences of bacterial diseases. The company leverages its cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc., to re-engineer highly complex conjugate and novel protein vaccines. This proprietary platform, which includes the XpressCF technology, enables precise antigen design and site-specific conjugation, bypassing the limitations of conventional cell-based manufacturing systems to deliver enhanced immunological benefits. Vaxcyte's primary pipeline focuses on broad-spectrum pneumococcal conjugate vaccines (PCVs) to prevent invasive pneumococcal disease (IPD) and pneumonia, alongside early-stage programs targeting other major bacterial pathogens.
Research as of 28 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Prioritizing and accelerating the clinical development of VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate, as the lead asset in Vaxcyte's pneumococcal franchise for both adult and pediatric indications [1.4.1].
Expected impact: Establish VAX-31 as a potential new standard-of-care PCV with the broadest serotype coverage in the clinic, covering ~95% of IPD circulating in U.S. adults aged 50+.
Establishing custom commercial fill-finish manufacturing capacity for Vaxcyte's broad-spectrum PCVs in the United States through a long-term agreement with Thermo Fisher Scientific at its Greenville, North Carolina facility.
Expected impact: Strengthen the domestic supply chain, enhance commercial readiness, and secure long-term U.S. commercial supply capacity.
Establishing global commercial manufacturing capacity for drug substances and key components of VAX-24 and VAX-31 through an expanded collaboration with Lonza, utilizing a custom-built suite in Lonza's Ibex Dedicate Biopark in Visp, Switzerland.
Expected impact: Provide dedicated, large-scale manufacturing capacity to meet potential long-term global market demand for both adult and pediatric populations.
Restarting and advancing the VAX-A1 program for Group A Strep into clinical development after a prior pause driven by capital constraints, leveraging the proprietary XpressCF cell-free protein synthesis platform.
Expected impact: Demonstrate clinical proof-of-concept for a novel prophylactic vaccine designed to prevent Group A Strep infections, for which there is currently no approved vaccine.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Vaxcyte holds exclusive worldwide rights to Sutro's proprietary XpressCF cell-free protein synthesis platform for vaccine development. In late 2023, Vaxcyte exercised an option to obtain direct control over the development and manufacture of cell-free extract, a key component of its PCV franchise.
Terms: Vaxcyte paid Sutro $75 million in cash to exercise the manufacturing rights option and is obligated to pay up to $60 million in additional cash upon the occurrence of certain regulatory milestones. Vaxcyte also pays a 4% royalty on worldwide aggregate net sales of licensed human vaccine products.
Lonza is Vaxcyte's primary global manufacturing partner, providing custom-built manufacturing suites in Visp, Switzerland, to produce drug substances and key components for VAX-24 and VAX-31.
Terms: Vaxcyte agreed to pay Lonza a CHF 27 million repurposing fee (to be credited back over a 10-year commercial production period) alongside ongoing pre-commercial and commercial manufacturing service fees.
Thermo Fisher serves as Vaxcyte's primary domestic partner for commercial fill-finish operations, providing custom commercial capacity for broad-spectrum PCVs at its Greenville, North Carolina facility.
Terms: Signifies a long-term U.S. commercial manufacturing commitment representing up to $1 billion in manufacturing and related services.